John de Koning

John de Koning is a Partner at EQT Life Sciences, one of Europe's leading healthcare investment firms, since 2006. In addition to this role, John serves as a Board Observer for Tubulis GmbH, xilis, and XyloCor Therapeutics, and holds Board Member positions at Visus Therapeutics, VarmX, eTheRNA Immunotherapies, and ONWARD. John was previously a Board Member at Aelin Therapeutics and worked as a General Partner at LSP prior to its acquisition by EQT. Educational credentials include a PhD in Oncology from Erasmus Medical Center Rotterdam, a MSc in Medical Biology from Utrecht University, and a postdoctoral fellowship at the University of California, San Francisco.